Thursday 11th June 1:30 pm - 5:00 pm
Introductory BPPV Course

Introduction to managing Benign paroxysmal positional vertigo (BPPV) – 11 June 2026 PM

Eldon Court (ED) – Newcastle upon Tyne, Newcastle Upon Tyne, Tyne and Wear, NE1 7YE

Benign Paroxysmal Positional Vertigo (BPPV) is one of the most common causes of dizziness and imbalance, significantly increasing fall risk - especially in older adults. Join our hands on practical course to help you demystify the physiology and management of BPPV with a focus on practical skills and case scenarios to help you to gain confidence to assess and treat patients.

Sold out! £105.00
Teaching in action
Wednesday 24th June 9:00 am - 4:30 pm
Leading An Empowered Organisation™ (LEO) (Internal Only)

LEO Programme – CH59 – June 2026 (Internal Only)

Eldon Court (ED) – Newcastle upon Tyne, Newcastle Upon Tyne, Tyne and Wear, NE1 7YE

Please note our Leading an Empowered Organisation™ (LEO) programme is a development opportunity for nursing, midwifery and allied health professional (NMAHP) staff working at Newcastle Hospitals only

Get tickets £545.00 Places remaining: 27

Kidney Cancer
Tuesday 7th July 1:30 pm - Tuesday 14th July 4:30 pm
Cancer courses

Demystifying the Science Behind Systemic Treatments for Prostate, Bladder and Kidney Cancers – July 2026

Virtual delivery via MS Teams

During this introduction to the science behind a wide variety of systemic treatments given to people with prostate, bladder, or kidney cancer, Dr Elaine Vickers will discuss current hormone therapies, immunotherapy and targeted treatments.

Get tickets £175.00 Places remaining: 20

3D illustration representing lung cancer
Tuesday 8th September 1:30 pm - Tuesday 15th September 4:30 pm
Cancer courses

Targeted treatments and immunotherapy for Lung Cancer – September 2026

Virtual delivery via MS Teams

A focus on modern systemic treatments for non-small cell lung cancer (NSCLC) as well as the gene faults that drive many NSCLCs; the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET, and RET; the immune system and checkpoint inhibitor group of immunotherapies, including PD-1, PD-L1 and CTLA-4 targeted antibody therapies

Get tickets £175.00 Places remaining: 18